{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:35Z","timestamp":1790996675878,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.rcsop.2024.100450","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T16:52:20Z","timestamp":1715100740000},"page":"100450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adherence to Parkinson's disease medication: A case study to illustrate reasons for non-adherence, implications for practice and engaging under-represented participants in research"],"prefix":"10.1016","volume":"14","author":[{"given":"Delyth","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Seage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.rcsop.2024.100450_bb0005","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1474-4422(18)30355-7","article-title":"The burden of Parkinson\u2019s disease: a worldwide perspective","volume":"17","author":"Rocca","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rcsop.2024.100450_bb0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fneur.2019.00218","article-title":"Parkinson\u2019s disease and the environment","volume":"10","author":"Ball","year":"2019","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100450_bb0015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ene.13803","article-title":"Non-motor symptoms in early Parkin\u2019on\u2019s disease with different motor subtypes and their associations with quality of life","volume":"26","author":"Huang","year":"2019","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-9158-1-10","article-title":"Drug therapy in patients with Parkinson\u2019s disease","volume":"1","author":"M\u00fcller","year":"2012","journal-title":"Transl Neurodegen"},{"issue":"6","key":"10.1016\/j.rcsop.2024.100450_bb0025","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jnc.12686","article-title":"Protective and toxic roles of dopamine in Parkin\u2019on\u2019s disease","volume":"129","author":"Segura-Aguilar","year":"2014","journal-title":"J Neurochem"},{"key":"10.1016\/j.rcsop.2024.100450_bb0030","unstructured":"National Institute for Health and Care Excellence (NICE) Cited in Joint Formulary Committee, 2024, London BMJ Group and Pharmaceutical Press https:\/\/bnf.nice.org.uk\/treatment-summaries\/parkinsons-disease\/."},{"issue":"20","key":"10.1016\/j.rcsop.2024.100450_bb0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.rcsop.2024.100450_bb0040","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.27465","article-title":"Frequency of mood and anxiety fluctuations in Parkin\u2019on\u2019s disease patients with motor fluctuations: a systematic review","volume":"33","author":"Van Der Velden","year":"2018","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100450_bb0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.gerinurse.2015.01.003","article-title":"Challenges and strategies of medication adherence in Parkin\u2019on\u2019s disease: a qualitative study","volume":"36","author":"Shin","year":"2015","journal-title":"Geriatr Nurs"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0050","first-page":"1","article-title":"Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson\u2019s disease","volume":"3","author":"Lakshminarayana","year":"2017","journal-title":"NPJ Parkinon\u2019s Dis"},{"issue":"5","key":"10.1016\/j.rcsop.2024.100450_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/mds.20041","article-title":"Drug adherence in Parkin\u2019on\u2019s disease","volume":"19","author":"Leopold","year":"2004","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.rcsop.2024.100450_bb0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/mds.20602","article-title":"Suboptimal medication adherence in Parkin\u2019on\u2019s disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100450_bb0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/mds.21831","article-title":"Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkin\u2019on\u2019s disease","volume":"23","author":"Kulkarni","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","article-title":"Medication adherence in patients with Parkinson\u2019s disease","volume":"29","author":"Malek","year":"2015","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.rcsop.2024.100450_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207583","article-title":"Medication adherence among patients with type 2 diabetes: a mixed methods study","volume":"13","author":"Aloudah","year":"2018","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.rcsop.2024.100450_bb0080","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/08870446.2016.1153640","article-title":"Can illness beliefs, from the common-sense model, prospectively predict adherence to self-management behaviours? A systematic review and meta-analysis","volume":"31","author":"Aujla","year":"2016","journal-title":"Psychol Health"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"Horne","year":"1999","journal-title":"Psychol Health"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jpsychores.2007.05.004","article-title":"Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity\u2013concerns framework","volume":"64","author":"Clifford","year":"2008","journal-title":"J Psychosom Res"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/08870440290001502","article-title":"Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication","volume":"17","author":"Horne","year":"2002","journal-title":"Psychol Health"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3233\/JPD-150765","article-title":"Development and validation of the Parkinson\u2019s disease medication beliefs scale (PD-Rx)","volume":"6","author":"Fleisher","year":"2016","journal-title":"J Parkinon\u2019s Dis"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.14802\/jmd.20147","article-title":"Factors associated with medication beliefs in patients with Parkinson\u2019s disease: a cross-sectional study","volume":"14","author":"Kim","year":"2021","journal-title":"J Mov Disord"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.sapharm.2020.03.004","article-title":"Enhancing community pharmacists\u2019 provision of medication adherence support to older adults: a mixed methods study using the theoretical domains framework","volume":"17","author":"Patton","year":"2021","journal-title":"Res Soc Adm Pharm"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026980","article-title":"Mapping of modifiable barriers and facilitators of medication adherence in bipolar disorder to the theoretical domains framework: a systematic review protocol","volume":"9","author":"Prajapati","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.rcsop.2024.100450_bb0120","article-title":"Using the theoretical domains framework to uncover the barriers and facilitators of medication adherence in Parkinson\u2019s disease","volume":"11","author":"Smith","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"7227","key":"10.1016\/j.rcsop.2024.100450_bb0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/bmj.320.7227.114","article-title":"Qualitative research in health care: analysing qualitative data","volume":"320","author":"Pope","year":"2000","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research","volume":"13","author":"Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.rcsop.2024.100450_bb0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11910-013-0382-z","article-title":"Medication nonadherence in Parkinson\u2019s disease","volume":"13","author":"Fleisher","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.rcsop.2024.100450_bb0140","series-title":"Dillon (National Centre for Social Research). Quality in Qualitative Evaluation: A Framework for Assessing Research Evidence","author":"Spencer","year":"2003"},{"key":"10.1016\/j.rcsop.2024.100450_bb0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/00002512-200421120-00004","article-title":"Medication non-adherence in the elderly","volume":"21","author":"Hughes","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.rcsop.2024.100450_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpsychores.2018.10.010","article-title":"The intentional non-adherence scale (INAS): initial development and validation","volume":"115","author":"Weinman","year":"2018","journal-title":"J Psychosom Res"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0155","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/brainsci13020272","article-title":"Could vitamins have a positive impact on the treatment of Parkinson\u2019s disease?","volume":"13","author":"Sandeep","year":"2023","journal-title":"Brain Sci"},{"key":"10.1016\/j.rcsop.2024.100450_bb0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ejcn.2016.181","article-title":"Intake of vitamin B before onset of Parkinson\u2019s disease and atypical parkinsonism and olfactory function at the time of diagnosis","volume":"71","author":"H\u00e5glin","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"1\u20132","key":"10.1016\/j.rcsop.2024.100450_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.02.008","article-title":"Thiamine and Parkinson's disease","volume":"316","author":"Luong","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.rcsop.2024.100450_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009289","article-title":"High-dose thiamine as initial treatment for Parkinson\u2019s disease","author":"Costantini","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100450_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.pec.2010.12.008","article-title":"Health information seeking: a review of measures and methods","volume":"82","author":"Anker","year":"2011","journal-title":"Patient Educ Couns"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100450_bb0180","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/1673-5374.179047","article-title":"An open-label pilot study with high-dose thiamine in Parkinson\u2019s disease","volume":"11","author":"Costantini","year":"2016","journal-title":"Neural Regen Res"},{"issue":"4","key":"10.1016\/j.rcsop.2024.100450_bb0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000126073","article-title":"Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status","volume":"77","author":"Joosten","year":"2008","journal-title":"Psychother Psychosom"},{"issue":"12","key":"10.1016\/j.rcsop.2024.100450_bb0190","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/acm.2014.0353","article-title":"Long-term treatment with high-dose thiamine in Parkinson disease: an open-label pilot study","volume":"21","author":"Costantini","year":"2015","journal-title":"J Altern Complement Med"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01173486","article-title":"Illness cognition: using common sense to understand treatment adherence and affect cognition interactions","volume":"16","author":"Leventhal","year":"1992","journal-title":"Cogn Ther Res"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100450_bb0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jpsychores.2008.02.008","article-title":"The prediction of self-care behaviors in end-stage renal disease patients using Leventhal\u2019s self-regulatory model","volume":"65","author":"O\u2019Connor","year":"2008","journal-title":"J Psychosom Res"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100450_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14941","article-title":"Understanding strategies to improve medication adherence among persons with type 2 diabetes: a scoping review","volume":"40","author":"Vallis","year":"2023","journal-title":"Diabet Med"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624000477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624000477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T03:00:58Z","timestamp":1718593258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276624000477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":41,"alternative-id":["S2667276624000477"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100450","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to Parkinson's disease medication: A case study to illustrate reasons for non-adherence, implications for practice and engaging under-represented participants in research","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100450"}}